data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

+ New Watchlist

Benzinga Research

-

-

-

-

-

-

-

Get Benzinga Pro
Data & APIs
Events
Marketfy
Premarket
Boost
Advertise

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRDgwMDI3IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHoiLz48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCAzMTIuODgyaDUxMnYxMTMuNzc1SDB6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZEQTQ0IiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBkPSJNMCA4NS4zMzFoNTEydjExMy43NzVIMHptMCAyMjcuNTUxaDUxMnYxMTMuNzc1SDB6IiBmaWxsPSIjRDgwMDI3Ii8+PC9zdmc+

data:image/svg+xml;base64,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

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMzQxLjMzNCA4NS4zM0gwdjM0MS4zMzJoNTEyVjg1LjMzeiIvPjxwYXRoIGZpbGw9IiM2REE1NDQiIGQ9Ik0wIDg1LjMzM2gxNzAuNjYzVjQyNi42N0gweiIvPjxwYXRoIGZpbGw9IiNEODAwMjciIGQ9Ik0zNDEuMzM3IDg1LjMzM0g1MTJWNDI2LjY3SDM0MS4zMzd6Ii8+PC9zdmc+

data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIHZpZXdCb3g9IjAgODUuMzMzIDUxMiAzNDEuMzMzIj48cGF0aCBmaWxsPSIjRkZGIiBkPSJNMCA4NS4zMzFoNTEydjM0MS4zMzdIMHoiLz48cGF0aCBmaWxsPSIjMDA1MkI0IiBkPSJNMCA4NS4zMzFoMTcwLjY2M3YzNDEuMzM3SDB6Ii8+PHBhdGggZmlsbD0iI0Q4MDAyNyIgZD0iTTM0MS4zMzcgODUuMzMxSDUxMnYzNDEuMzM3SDM0MS4zMzd6Ii8+PC9zdmc+

Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Government
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Options
Binary Options
Bonds
Futures
CME Group
Global Economics
Previews
Small-Cap
Real Estate
Cryptocurrency
Penny Stocks
Digital Securities
Volatility
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Covey Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Yield
How to Buy Corporate Bonds
How to Buy Treasury Bonds
How to Invest in Real Estate Online
Money
Compare Online Brokers
Stock Brokers
Forex Brokers
Futures Brokers
Crypto Brokers
Options Brokers
ETF Brokers
Mutual Fund Brokers
Index Fund Brokers
Bond Brokers
Short Selling Brokers
Stock Apps
All Broker Reviews
Insurance
Auto
Home
Medicare
Life
Vision
Dental
Business
Pet
Health
Motorcycle
Renters
Workers Comp
Top Stocks
Penny Stocks
Stocks Under $5
Stocks Under $10
Stocks Under $20
Stocks Under $50
Stocks Under $100
Alternative Investing
Invest in Art
Invest in Watches
Invest in Land
Invest in Real Estate
Invest in Wine
Invest in Gold
Mortgages
Refinance
Purchase
Find a Mortgage Broker
Alts
Alternative Investment Platforms
REITs Versus Crowdfunding
How to Invest in Artwork
How to Invest in Jewelry
Best Real Estate Crowdfunding Platforms
Best Alternative Investments
Best Alternative Investment Platforms
Crypto
Get Started
Is Bitcoin a Good Investment?
Is Ethereum a Good Investment?
What is Blockchain
Best Altcoins
How to Buy Cryptocurrency?
DeFi
Crypto and DeFi 101
What is DeFi?
Decentralized Exchanges
Best DeFi Yield Farms
Digital Securities
NFTs
NFT Release Calendar
What is a Non-Fungible Token (NFT)?
How to Buy Non-Fungible Tokens (NFTs)
CryptoPunks Watchlist
Are NFTs a Scam or a Digital Bubble?
Best In Crypto
Best Crypto Apps
Best Crypto Portfolio Trackers
Best Crypto Day Trading Strategies
Best Crypto IRA
Best Cryptocurrency Scanners
Best Business Crypto Accounts
Best Crypto Screeners
Cannabis
Cannabis Conference
News
Earnings
Interviews
Deals
Regulations
Psychedelics
Jobs

Free Benzinga Pro Trial

Calendars

Analyst Ratings Calendar

Conference Call Calendar

Dividend Calendar

Earnings Calendar

Economic Calendar

Guidance Calendar

Stock Split Calendar

Trade Ideas

Trade Idea Feed

Analyst Ratings

Unusual Options Activity

Free Newsletter

Short Interest

Largest Increase

Largest Decrease

Calculators

Margin Calculator

Forex Profit Calculator

100x Options Profit Calculator

-

-

-

-

-

-

-

Arcellx Inc

(NASDAQ:ACLX)

Perks Buy Compare Brokers

$58.05

0.16[0.28%]

Last update: 3:11PM (Delayed 15-Minutes)
Get Real Time Here

$58.15

0.1000[0.17%]

After-Hours

Perks Buy Compare Brokers

Open57.890	Close-
Vol / Avg.806.282K / 632.419K	Mkt Cap2.826B
Day Range57.550 - 59.085	52 Wk Range18.810 - 57.900

0

Latest News for Arcellx Stock (NASDAQ:ACLX)

Arcellx Stock (NASDAQ: ACLX)

Categories: All

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

All News

General

Contracts

Dividends

Events

FDA

M&A

Offerings

Stock Split

Media

Buybacks

Insider Trades

Earnings

Guidance

Analyst Ratings

Trading Ideas

Wednesday, November 15, 2023

HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $60
Benzinga Newsdesk - Nov 15, 2023, 1:48PM
Needham Maintains Buy on Arcellx, Raises Price Target to $60
Benzinga Newsdesk - Nov 15, 2023, 1:34PM
Kite, A Gilead Company, And Arcellx Have Expanded Their Existing Collaboration, Which Was Originally Announced In December 2022, For CART-ddBCMA To Include Lymphomas; Arcellx To Receive $200M Equity Investment And $85M Upfront Cash Payment
Benzinga Newsdesk - Nov 15, 2023, 6:03AM

Monday, November 13, 2023

Arcellx Q3 EPS $(0.81) Misses $(0.65) Estimate, Sales $14.96M Beat $11.22M Estimate
Benzinga Newsdesk - Nov 13, 2023, 5:04PM

Thursday, November 02, 2023

Why STAAR Surgical Shares Are Trading Lower By Around 16%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Lisa Levin - Nov 2, 2023, 2:26PM
Why Is Blood Cancer Focused Arcellx Stock Trading Higher Today?
Vandana Singh - Nov 2, 2023, 12:39PM
Starbucks, Teleflex, Roku, Shopify And Other Big Stocks Moving Higher On Thursday
Lisa Levin - Nov 2, 2023, 11:01AM

Monday, October 30, 2023

TD Cowen Initiates Coverage On Arcellx with Outperform Rating
Benzinga Newsdesk - Oct 30, 2023, 9:54AM

Tuesday, October 17, 2023

Benzinga's Top Ratings Upgrades, Downgrades For October 17, 2023
Benzinga Insights - Oct 17, 2023, 11:00AM
UBS Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $52
Benzinga Newsdesk - Oct 17, 2023, 7:53AM

Tuesday, August 15, 2023

Analysts Stay Bullish On Arcellx's CART-ddBCMA's Long-term Therapeutic Potential
Vandana Singh - Aug 15, 2023, 2:42PM
FDA Gives Green Signal To Arcellx's Stopped Blood Cancer Study
Vandana Singh - Aug 15, 2023, 9:05AM
Baird Maintains Outperform on Arcellx, Raises Price Target to $52
Benzinga Newsdesk - Aug 15, 2023, 8:57AM
Stifel Maintains Buy on Arcellx, Lowers Price Target to $52
Benzinga Newsdesk - Aug 15, 2023, 8:33AM
Needham Reinstates Buy on Arcellx, Maintains $51 Price Target
Benzinga Newsdesk - Aug 15, 2023, 7:18AM
HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $50
Benzinga Newsdesk - Aug 15, 2023, 6:43AM

Monday, August 14, 2023

12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga Insights - Aug 14, 2023, 5:32PM
Arcellx Q2 EPS $(0.50) Misses $(0.31) Estimate, Sales $14.30M Miss $40.55M Estimate
Benzinga Newsdesk - Aug 14, 2023, 4:38PM
Arcellx Announced The FDA Has Lifted The Partial Clinical Hold Placed On CART-ddBCMA investigational New Drug For The Treatment Of Patients With Relapsed Or Refractory Multiple Myeloma
Benzinga Newsdesk - Aug 14, 2023, 4:36PM

Tuesday, August 08, 2023

Arcellx Chief Medical Officer Trades $106K In Company Stock
Benzinga Insights - Aug 8, 2023, 11:02AM

Thursday, July 06, 2023

Chief Medical Officer of Arcellx Makes $95K Sale
Benzinga Insights - Jul 6, 2023, 11:02AM

Friday, June 23, 2023

Needham Reiterates Buy on Arcellx, Maintains $51 Price Target
Benzinga Newsdesk - Jun 23, 2023, 6:05AM

Wednesday, June 21, 2023

Canaccord Genuity Reiterates Buy on Arcellx, Maintains $49 Price Target
Benzinga Newsdesk - Jun 21, 2023, 9:25AM
HC Wainwright & Co. Reiterates Buy on Arcellx, Maintains $49 Price Target
Benzinga Newsdesk - Jun 21, 2023, 4:56AM

Tuesday, June 20, 2023

Guggenheim Maintains Buy on Arcellx
Benzinga Newsdesk - Jun 20, 2023, 1:13PM
HC Wainwright & Co. Reiterates Buy on Arcellx, Maintains $49 Price Target
Benzinga Newsdesk - Jun 20, 2023, 1:12PM
Why Surgalign Holdings Shares Are Trading Lower By Around 75%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Lisa Levin - Jun 20, 2023, 1:07PM
Analyst Ratings for Arcellx
Benzinga Insights - Jun 20, 2023, 1:02PM
Why Arcellx (ACLX) Stock Is Nosediving
Henry Khederian - Jun 20, 2023, 10:04AM
Truist Securities Maintains Buy on Arcellx, Lowers Price Target to $57
Benzinga Newsdesk - Jun 20, 2023, 9:10AM
Arcellx's Lead Product Candidate Hit By FDA Clinical Hold For Multiple Myeloma, Stock Falls
Vandana Singh - Jun 20, 2023, 8:19AM
Why Cano Health Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Lisa Levin - Jun 20, 2023, 8:10AM
Arcellx shares are trading lower after the FDA on Monday put a clinical hold on the company's multiple myeloma phase 2 trial.
Benzinga Newsdesk - Jun 20, 2023, 7:59AM
Alibaba, Arcellx And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
Lisa Levin - Jun 20, 2023, 6:39AM
Needham Reiterates Buy on Arcellx, Maintains $51 Price Target
Benzinga Newsdesk - Jun 20, 2023, 6:17AM

Monday, June 19, 2023

Arcellx Announces Clinical Hold For Its iMMagine-1 Phase 2 Clinical Program; FDA Has Provided Clearance To The Co To Continue Dosing Patients Who Have Already Undergone Lymphodepletion
Happy Mohamed - Jun 19, 2023, 7:51PM

Thursday, May 18, 2023

The Latest Analyst Ratings for Arcellx
Benzinga Insights - May 18, 2023, 11:01AM
Benzinga's Top Ratings Upgrades, Downgrades For May 18, 2023
Benzinga Insights - May 18, 2023, 11:00AM
Truist Securities Initiates Coverage On Arcellx with Buy Rating, Announces Price Target of $60
Benzinga Newsdesk - May 18, 2023, 6:29AM

Tuesday, May 16, 2023

10% Owner At This Health Care Company Sells $45.59M of Stock
Benzinga Insights - May 16, 2023, 11:04AM
Arcellx Director Trades Company's Stock
Benzinga Insights - May 16, 2023, 11:04AM

Wednesday, May 10, 2023

B of A Securities Maintains Buy on Arcellx, Raises Price Target to $50
Benzinga Newsdesk - May 10, 2023, 10:34AM

Tuesday, May 09, 2023

Chief Medical Officer of Arcellx Sold $54K In Stock
Benzinga Insights - May 9, 2023, 11:03AM
HC Wainwright & Co. Maintains Buy on Arcellx, Raises Price Target to $49
Benzinga Newsdesk - May 9, 2023, 6:29AM
Needham Maintains Buy on Arcellx, Raises Price Target to $51
Benzinga Newsdesk - May 9, 2023, 6:09AM
Barclays Maintains Overweight on Arcellx, Raises Price Target to $49
Benzinga Newsdesk - May 9, 2023, 5:51AM

Monday, May 08, 2023

Arcellx Inc Files For Mixed Shelf; Size Not Disclosed
Charles Gross - May 8, 2023, 5:09PM
Arcellx Q1 EPS $(0.58) Misses $1.82 Estimate
Benzinga Newsdesk - May 8, 2023, 4:28PM

Wednesday, April 26, 2023

Arcellx shares are trading higher after Canaccord Genuity maintained a Buy rating on the stock and raised its price target from $40 to $49.
Michael Horton - Apr 26, 2023, 12:40PM
Canaccord Genuity Maintains Buy on Arcellx, Raises Price Target to $49
Benzinga Newsdesk - Apr 26, 2023, 11:38AM

1
2
3
4
5
6
7
Next
17

Popular Channels

PreMarket Prep
Press Releases
Analyst Ratings
News
Options
ETFs

Tools & Features

Real Time Feed
Public RSS Feeds
Submit News Tips
Blog
Embeddable Finance Widgets & Tools
Benzinga Catalyst

Partners & Contributors

Affiliate Program
Contributor Portal
Licensing & Syndication
Sponsored Content
Advertise With Us
Lead Generation & SEO

About Benzinga

About Us
Careers
In The News
Events
Contact Us

Terms & Conditions
Do Not Sell My Personal Data/Privacy Policy
Disclaimer
Service Status
Sitemap

© 2023 Benzinga | All Rights Reserved